ATE497975T1 - Il-21-varianten - Google Patents

Il-21-varianten

Info

Publication number
ATE497975T1
ATE497975T1 AT06763042T AT06763042T ATE497975T1 AT E497975 T1 ATE497975 T1 AT E497975T1 AT 06763042 T AT06763042 T AT 06763042T AT 06763042 T AT06763042 T AT 06763042T AT E497975 T1 ATE497975 T1 AT E497975T1
Authority
AT
Austria
Prior art keywords
amino acids
variants
deleting
seq
peptide
Prior art date
Application number
AT06763042T
Other languages
English (en)
Inventor
Siv Hjorth
Kent Bodensgaard
Dennis Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE497975T1 publication Critical patent/ATE497975T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06763042T 2005-04-18 2006-04-18 Il-21-varianten ATE497975T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500562 2005-04-18
PCT/EP2006/061635 WO2006111524A2 (en) 2005-04-18 2006-04-18 Il-21 variants

Publications (1)

Publication Number Publication Date
ATE497975T1 true ATE497975T1 (de) 2011-02-15

Family

ID=36950214

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06763042T ATE497975T1 (de) 2005-04-18 2006-04-18 Il-21-varianten

Country Status (17)

Country Link
US (2) US8034326B2 (de)
EP (2) EP2360181B1 (de)
JP (2) JP2008538290A (de)
KR (1) KR20080013878A (de)
CN (1) CN101180315A (de)
AT (1) ATE497975T1 (de)
AU (1) AU2006237329B2 (de)
BR (1) BRPI0609079A2 (de)
CA (1) CA2604222A1 (de)
DE (1) DE602006020032D1 (de)
ES (1) ES2357550T3 (de)
IL (1) IL186265A0 (de)
MX (1) MX2007012887A (de)
NO (1) NO20075927L (de)
RU (1) RU2412199C2 (de)
WO (1) WO2006111524A2 (de)
ZA (1) ZA200708407B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
AU2006237329B2 (en) 2005-04-18 2012-04-12 Novo Nordisk A/S IL-21 variants
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
EP2109620B1 (de) 2006-12-21 2012-08-22 Novo Nordisk A/S Interleukin-21-varianten mit geänderter bindung an den il-21-rezeptor
US20100111851A1 (en) * 2007-01-05 2010-05-06 The University Of Tokyo Diagnosis and treatment of cancer by using anti-prg-3 antibody
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
KR100902340B1 (ko) * 2007-08-02 2009-06-12 한국생명공학연구원 Yc-1 또는 il-21을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
JP2012514586A (ja) * 2009-01-05 2012-06-28 フラウンホーファーゲゼルシャフト ツール フォルデルング デル アンゲヴァンテン フォルシユング エー.フアー. Il−21およびil−21変異体に基づく抗体欠乏性疾患を治療するための手段および方法
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
EP3978512A1 (de) 2015-10-09 2022-04-06 Bioniz, LLC Modulation der gamma-c-zytokin-aktivität
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
KR102707650B1 (ko) 2017-04-07 2024-09-19 바이오니즈 테라퓨틱스, 아이엔씨. 감마-c-사이토카인 활성의 안정한 조절자
CN118126157A (zh) 2017-08-03 2024-06-04 美国安进公司 白介素-21突变蛋白和治疗方法
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
EP3765517A1 (de) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. An calreticulin bindende multifunktionsmoleküle und ihre verwendungen
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN111205361B (zh) 2018-11-22 2022-05-06 海珂分子(北京)科技有限责任公司 白介素21蛋白(il21)突变体及其应用
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド NKp30に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
BR112021021878A2 (pt) 2019-05-03 2022-01-18 Bioniz Llc Modulação dos efeitos de sinalização da gama-c-citocina para tratamento da alopecia e distúrbios associados
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
CN115232797A (zh) * 2021-04-23 2022-10-25 南京北恒生物科技有限公司 工程化免疫细胞及其用途
WO2022245500A1 (en) 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
KR20230044130A (ko) 2021-09-24 2023-04-03 바이오엔시스템스 주식회사 Pd-1 및 il-21을 포함하는 융합단백질 이량체 및 이의 용도
KR102796245B1 (ko) * 2022-05-10 2025-04-18 아주대학교산학협력단 인터루킨21 변이체, 이를 포함하는 융합단백질 및 이의 용도
WO2024002170A1 (en) * 2022-06-29 2024-01-04 Beijing Neox Biotech Limited Il-21 polypeptides and methods of use
CN117210411A (zh) * 2023-09-13 2023-12-12 中国科学院生物物理研究所 一种免疫细胞及其表达载体、应用和制备方法
WO2025109155A1 (en) * 2023-11-24 2025-05-30 Prokarium Limited Interleukin variant
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191139A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of her2-specific antigen binding proteins and cytokines
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
CN118546233B (zh) * 2024-07-30 2024-10-18 成都微芯新域生物技术有限公司 白介素-21突变体及其应用
WO2026087748A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof
WO2026087747A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203570A (en) 1978-08-23 1980-05-20 The Western States Machine Company Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
JPS60501140A (ja) 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
JP2523562B2 (ja) 1985-10-25 1996-08-14 ザイモジェネティックス インコーポレーテッド 外来タンパク質を分泌することを目的としたbar1の使用法
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
DE3856247T2 (de) 1987-07-24 1999-04-29 Chiron Corp., Emeryville, Calif. Züchtung von insektenzellen mit airlift-reaktoren
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
AU4647889A (en) 1988-11-18 1990-06-12 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
DK300090D0 (da) 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
US5494662A (en) 1992-04-27 1996-02-27 Ono Pharmaceutical Co., Ltd. Stimulator for bone formation
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
MY124565A (en) * 1996-07-19 2006-06-30 Bayer Corp High-affinity interleukin-4-muteins
DE69921102T2 (de) 1998-03-05 2006-02-02 Chiron Corp., Emeryville Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US20010023070A1 (en) 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
JP2002516103A (ja) 1998-05-29 2002-06-04 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド インターロイキン21およびインターロイキン22
PT1974747E (pt) 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
UA84387C2 (ru) 1999-03-09 2008-10-27 Займодженетикс, Инк. Человеческий цитокин как лиганд зальфа рецептора и его применение
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
EP3254687A1 (de) 2001-10-04 2017-12-13 Genetics Institute LLC Verfahren und zusammensetzungen zur modulation der interleukin-21-rezeptoraktivität
EP2130919A1 (de) 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21-Antagonisten
OA13063A (en) 2001-11-20 2006-11-10 Pharmacia Corp Chemically-modified human growth hormone conjugates.
CA2481304A1 (en) 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
AU2003230834A1 (en) 2002-04-09 2003-10-27 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
MXPA04012116A (es) 2002-06-07 2005-04-19 Zymogenetics Inc Uso del il-21 en cancer y otras aplicaciones terapeuticas.
AU2003282955A1 (en) 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
MXPA05006117A (es) 2002-12-13 2005-09-30 Zymogenetics Inc Produccion de il-21 en hospederos procarioticos.
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
RU2005132458A (ru) * 2003-03-21 2006-03-20 Уайт (Us) Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21
PL1625156T3 (pl) 2003-05-12 2013-03-29 Affymax Inc Peptydy wiążące się do receptora erytropoetyny
CA2529520A1 (en) 2003-06-19 2004-12-29 Centocor, Inc. Interleukin-21 analogs
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
DE602004029173D1 (de) 2003-10-10 2010-10-28 Novo Nordisk As Il-21-derivate
EP1692276B1 (de) 2003-11-19 2010-07-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Verfahren zur induktion der entwicklung und terminalen differenzierung von gedächtnis-b-zellen
EP1753458A4 (de) 2004-05-19 2009-07-22 Wyeth Corp Modulation der immunglobulinproduktion und atopische erkrankungen
MX2007001509A (es) 2004-08-05 2007-03-27 Wyeth Corp Antagonismo de la actividad del receptor de interleuquina 21.
AU2006237329B2 (en) * 2005-04-18 2012-04-12 Novo Nordisk A/S IL-21 variants
EP2109620B1 (de) 2006-12-21 2012-08-22 Novo Nordisk A/S Interleukin-21-varianten mit geänderter bindung an den il-21-rezeptor

Also Published As

Publication number Publication date
EP2360181B1 (de) 2013-09-18
WO2006111524A2 (en) 2006-10-26
EP1877439B1 (de) 2011-02-09
US20120082996A1 (en) 2012-04-05
WO2006111524A3 (en) 2006-12-07
NO20075927L (no) 2007-12-07
JP2008538290A (ja) 2008-10-23
US20090035254A1 (en) 2009-02-05
EP1877439A2 (de) 2008-01-16
ES2357550T3 (es) 2011-04-27
MX2007012887A (es) 2007-12-10
AU2006237329B2 (en) 2012-04-12
RU2412199C2 (ru) 2011-02-20
KR20080013878A (ko) 2008-02-13
JP2012070742A (ja) 2012-04-12
RU2007136026A (ru) 2009-05-27
CN101180315A (zh) 2008-05-14
IL186265A0 (en) 2008-01-20
BRPI0609079A2 (pt) 2010-11-16
ZA200708407B (en) 2008-10-29
US8034326B2 (en) 2011-10-11
CA2604222A1 (en) 2006-10-26
EP2360181A1 (de) 2011-08-24
DE602006020032D1 (de) 2011-03-24
AU2006237329A1 (en) 2006-10-26
US8383367B2 (en) 2013-02-26

Similar Documents

Publication Publication Date Title
NO20075927L (no) IL-21 varianter
DK1476541T3 (da) Cytokin (zcytor17-ligand)
ATE462003T1 (de) Aus wt1 stammende krebsantigenpeptide
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
DE602005008996D1 (de) Radiofluorierte peptide
NZ596658A (en) Dig-10 insecticidal cry toxins
EP2865387A3 (de) Priming einer Immunantwort
NZ595303A (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
DE602007004110D1 (de) Hausstaubmilbenallergen
DE60322613D1 (de) Frostschutzproteine aus Basidiomyceten
ECSP066495A (es) Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)
DK2076532T3 (da) Cytokinderivater
ITMI20030789A1 (it) Valvola di iniezione di comustibile.
BRPI0413437A (pt) preparação de peptìdeos de somatostatina
JP2005535281A5 (de)
DE602007006493D1 (de) Peptide mit proliferationshemmender wirkung
EP1497307A4 (de) Impfstoff mit rekombinantem p.falciparum-merozoitprotein-1 42
EP1567542A4 (de) Neue, mit inhibin verwandte multiantigenepeptidzusammensetzungen, die die produktionsleistung von vögeln erhöhen
DE60229966D1 (de) Diabetesmodell
GB0409559D0 (en) Polypeptide
DE602006017806D1 (de) Behandlung von neurodegeneration
ATE441865T1 (de) Neue polypeptide zur in-vintro-isolierung und vorbeugung von infektionen mit legionella pneumophila
DK1794294T3 (da) Rekombinant carboxypeptidase B
FR2874025B1 (fr) Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a legionella pneumophila
PT1537210E (pt) Inibicao de oliconucleotidos decoy de expressao cd-40

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1877439

Country of ref document: EP